Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oral Capecitabine Exposures and Use of Uridine Triacetate: A 20-Year Retrospective Analysis.

Clinical drug investigation - 1 May 2023

Seltzer Justin A, Friedman Nathan A, Hardin Jeremy, Galust Henrik, Cantrell F Lee, Minns Alicia

Abstract excerpt

BACKGROUND AND OBJECTIVES: Capecitabine is an oral prodrug of 5-fluorouracil. Toxicity can occur during therapy as well as acutely with overdose and particular genetic susceptibilities. Uridine triacetate is an effective antidote if given within 96 h of exposure. This study seeks to characterize accidental and intentional capecitabine exposures and uridine triacetate use, about which little has been published....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Capecitabine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Predisposition to Disease

Source

Open in PubMed Open full text

Identifiers

PMID: 37072662
DOI: 10.1007/s40261-023-01268-5
PMCID: PMC10198921

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oral Capecitabine Exposures and Use of Uridine Triacetate: A 20-Year Retrospective Analysis.PMID 37072662Read ↗

Review of the Fluoropyrimidine Antidote Uridine TriacetateSemantic proximity Read ↗

Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature.Semantic proximity Read ↗

Early-Onset 5-Fluorouracil Toxicity in a Patient Negative for Dihydropyrimidine Dehydrogenase Mutations: The Clinical Course of Reversal with Uridine Triacetate.Semantic proximity Read ↗

Tolerance to oral anticancer agent treatment in older adults with cancer: A secondary analysis of data from EHRs and a pilot study of patient-reported outcomesSemantic proximity Read ↗

New Serious Safety Warnings of Targeted Anticancer Agents After Their Initial FDA ApprovalSemantic proximity Read ↗

Clinical characterization of 145 cases of botulinum toxin injection-induced cosmetic poisoningSemantic proximity Read ↗

Human poisonings with neonicotinoid pesticides – frequency and severity show public health risks, regulatory failuresSemantic proximity Read ↗

Shielding Effects of Aspirin Use from Adverse in Hospital Outcomes in Non-Metastatic Pancreatic Cancer: An Evaluation of the National Inpatient SampleSemantic proximity Read ↗

The Cancer Treatment Helpline – a retrospective study of the NHS Tayside ExperienceSemantic proximity Read ↗

Comparison of a thymine challenge test and endogenous uracil-dihydrouracil levels for assessment of fluoropyrimidine toxicity risk.Semantic proximity Read ↗

Relatively mild symptoms after chronic overdose with a double-dose encorafenib: a case report.Semantic proximity Read ↗

ONE-CARBON METABOLISM AND CHEMOTHERAPY-INDUCED TOXICITIES IN PATIENTS WITH STAGE II-III COLORECTAL CANCERSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.